WO1996040048A3 - Novel uses for thyroid hormones or thyroid hormone-like compounds - Google Patents
Novel uses for thyroid hormones or thyroid hormone-like compounds Download PDFInfo
- Publication number
- WO1996040048A3 WO1996040048A3 PCT/US1996/009975 US9609975W WO9640048A3 WO 1996040048 A3 WO1996040048 A3 WO 1996040048A3 US 9609975 W US9609975 W US 9609975W WO 9640048 A3 WO9640048 A3 WO 9640048A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thyroid hormone
- thyroid
- compound
- concentration
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69630380T DE69630380T8 (en) | 1995-06-07 | 1996-06-07 | NEW USES OF THYROID HORMONES OR THYROIDHORMONE SIMILAR COMPOUNDS |
AU64769/96A AU6476996A (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormones or thyroid hormone-like comp ounds |
DK96924268T DK0831769T3 (en) | 1995-06-07 | 1996-06-07 | New uses of thyroid hormones or thyroid hormone-like compounds |
EP96924268A EP0831769B2 (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormones or thyroid hormone-like compounds |
JP9502122A JPH11508241A (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormone or thyroid hormone-like compounds |
AT96924268T ATE251887T1 (en) | 1995-06-07 | 1996-06-07 | NEW USES OF THYROID HORMONES OR THYROID HORMONES SIMILAR COMPOUNDS |
US08/973,627 US6221911B1 (en) | 1995-06-07 | 1996-06-07 | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
CA002223720A CA2223720C (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormones or thyroid hormone-like compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48169895A | 1995-06-07 | 1995-06-07 | |
US08/481,698 | 1995-06-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US48169895A Continuation-In-Part | 1995-06-07 | 1995-06-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/973,627 A-371-Of-International US6221911B1 (en) | 1995-06-07 | 1996-06-07 | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
US09/617,052 Continuation-In-Part US6380255B1 (en) | 1995-06-07 | 2000-07-14 | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1996040048A2 WO1996040048A2 (en) | 1996-12-19 |
WO1996040048A9 WO1996040048A9 (en) | 1997-03-27 |
WO1996040048A3 true WO1996040048A3 (en) | 1997-11-13 |
Family
ID=23913014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009975 WO1996040048A2 (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormones or thyroid hormone-like compounds |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1398024A3 (en) |
JP (1) | JPH11508241A (en) |
AT (1) | ATE251887T1 (en) |
AU (1) | AU6476996A (en) |
CA (1) | CA2223720C (en) |
DE (1) | DE69630380T8 (en) |
DK (1) | DK0831769T3 (en) |
ES (1) | ES2208753T5 (en) |
PT (1) | PT831769E (en) |
WO (1) | WO1996040048A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380255B1 (en) * | 1995-06-07 | 2002-04-30 | Karo Bio Ab | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
EP0907351B2 (en) * | 1996-03-29 | 2012-04-18 | Keyvest GmbH | Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite |
JP3345428B2 (en) | 1996-08-20 | 2002-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Treatment of the eye using the synthetic thyroid forman composition |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
ATE330590T1 (en) * | 1999-04-26 | 2006-07-15 | Elliot Danforth Jr | PHARMACEUTICAL COMPOSITIONS CONTAINING TETRAC AND METHOD OF USE THEREOF |
US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
EP1253966B1 (en) * | 1999-08-13 | 2011-04-27 | Curadis GmbH | Substances and agents for positively influencing collagen |
US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
FI107018B (en) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatological use and dermatological preparation |
AU2002331145B2 (en) * | 2001-08-24 | 2008-07-10 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
CA2539288C (en) * | 2003-09-15 | 2015-05-12 | Shaker A. Mousa | Thyroid hormone analogs and methods of use |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
JP2007512359A (en) | 2003-11-19 | 2007-05-17 | メタバシス・セラピューティクス・インコーポレイテッド | Novel phosphorus-containing thyroid hormone-like substance |
MX2007014502A (en) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Thyromimetics for the treatment of fatty liver diseases. |
US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
US20100209382A1 (en) | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
WO2007059039A1 (en) * | 2005-11-11 | 2007-05-24 | Oregon Health & Science University | Thyroxine derivatives for preconditioning against stroke |
CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
EP2120913B1 (en) | 2006-12-22 | 2015-01-21 | NanoPharmaceuticals LLC | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
WO2015074050A1 (en) | 2013-11-18 | 2015-05-21 | Nanopharmaceuticals Llc | Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof |
BR112017010778A2 (en) | 2014-11-25 | 2018-01-09 | Trophea Dev Ab | skin atrophy treatment with a combination of triiodothyroacetic acid (triac) and dehydroepiandrosterone (dhea) |
CN109715551A (en) | 2016-06-07 | 2019-05-03 | 纳米药业有限责任公司 | With 3 integrin throstatics of α v β conjugation can not polymer pyrolysis |
JP2020500199A (en) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | Methods of treating glycogen storage disease |
EA201992703A1 (en) | 2017-06-05 | 2020-04-15 | Вайкинг Терапьютикс, Инк. | COMPOSITIONS FOR TREATING FIBROSIS |
CN112135832A (en) | 2018-03-22 | 2020-12-25 | 维京治疗公司 | Crystalline forms of a compound and methods of making crystalline forms of a compound |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE515812A (en) * | ||||
GB782745A (en) * | 1953-08-13 | 1957-09-11 | Arthur Alfred Hellbaum | Improvements in or relating to pharmaceutical compositions |
GB859546A (en) * | 1956-05-29 | 1961-01-25 | Arthur Alfred Hellbaum | Composition for treatment of the skin |
FR6656M (en) * | 1967-02-23 | 1969-01-27 | ||
FR2139748A1 (en) * | 1971-06-03 | 1973-01-12 | Prugnaud Robert | |
FR2153202A1 (en) * | 1971-09-24 | 1973-05-04 | Ind Chimique | Triiodothyroacetic acid salts prepn - with metals and organic bases |
FR2354101A1 (en) * | 1976-06-10 | 1978-01-06 | Berema Sa | PREPARATION FOR TREATING FAT OVERLOAD AND CELLULITIC INFILTRATES |
FR2357246A1 (en) * | 1976-07-09 | 1978-02-03 | Martinez Gerard | Antiinflammatory and analgesic medicaments - contg. hydrolase, thyroxine and adrenalin and applied topically |
RO76691A2 (en) * | 1979-04-02 | 1981-08-30 | Intreprinderea De Produse Cosmetice "Farmec",Ro | NUTRITIVE CREAM AGAINST WRINKLES |
EP0060776A1 (en) * | 1981-03-11 | 1982-09-22 | Somachim S.A. | Medicaments for the treatment of obesity and hyperlipoidemia |
CH642851A5 (en) * | 1980-02-13 | 1984-05-15 | Berema Sa | Medicinal compositions for the treatment of cellulite |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3198702A (en) * | 1960-03-17 | 1965-08-03 | Arthur A Hellbaum | Method for treating skin burns |
FR3111M (en) * | 1963-12-02 | 1965-02-08 | Rech S Pharma Et Scient | Medicinal product based on a cysteine derivative. |
FR2160258A1 (en) * | 1971-11-16 | 1973-06-29 | Egema | Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis |
GB1400851A (en) * | 1971-06-23 | 1975-07-16 | Egema Sa | Triidothyroalkyl compounds their method of preparation and therapeutical compositions containing such compounds |
FR2142675A1 (en) * | 1971-06-23 | 1973-02-02 | Egema Sa | Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis |
FR2197577A1 (en) * | 1972-08-30 | 1974-03-29 | Ind Chimi Ue Sa | Hypocholesterolaemic, antiatheroma agents - 3,5-diiodo-4-(3-iodo-4-alkoxy-carbonyl phenoxy) phenylalkanoic acids, esters and salts |
FR2356427A2 (en) * | 1976-07-02 | 1978-01-27 | Ana Laboratoires | Compsn. for treatment of cellulitis and lipidic excess - contains mucopolysaccharidases opt. with hyaluronidase and active cpds. such as triiodo-thyroacetic acid, acetazolamide and aescin |
GB1587638A (en) * | 1977-06-03 | 1981-04-08 | Berema Sa | Iodophenoxyphenylalkenoic acid derivatives and pharmaceutical preparations containing them |
FI107018B (en) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatological use and dermatological preparation |
-
1996
- 1996-06-07 EP EP03022417A patent/EP1398024A3/en not_active Withdrawn
- 1996-06-07 PT PT96924268T patent/PT831769E/en unknown
- 1996-06-07 CA CA002223720A patent/CA2223720C/en not_active Expired - Fee Related
- 1996-06-07 EP EP96924268A patent/EP0831769B2/en not_active Expired - Lifetime
- 1996-06-07 AU AU64769/96A patent/AU6476996A/en not_active Abandoned
- 1996-06-07 ES ES96924268T patent/ES2208753T5/en not_active Expired - Lifetime
- 1996-06-07 DK DK96924268T patent/DK0831769T3/en active
- 1996-06-07 AT AT96924268T patent/ATE251887T1/en not_active IP Right Cessation
- 1996-06-07 JP JP9502122A patent/JPH11508241A/en active Pending
- 1996-06-07 WO PCT/US1996/009975 patent/WO1996040048A2/en active IP Right Grant
- 1996-06-07 DE DE69630380T patent/DE69630380T8/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE515812A (en) * | ||||
GB782745A (en) * | 1953-08-13 | 1957-09-11 | Arthur Alfred Hellbaum | Improvements in or relating to pharmaceutical compositions |
GB859546A (en) * | 1956-05-29 | 1961-01-25 | Arthur Alfred Hellbaum | Composition for treatment of the skin |
FR6656M (en) * | 1967-02-23 | 1969-01-27 | ||
FR2139748A1 (en) * | 1971-06-03 | 1973-01-12 | Prugnaud Robert | |
GB1354263A (en) * | 1971-06-03 | 1974-06-05 | Theranol Lab | Therapeutic composition |
FR2153202A1 (en) * | 1971-09-24 | 1973-05-04 | Ind Chimique | Triiodothyroacetic acid salts prepn - with metals and organic bases |
FR2354101A1 (en) * | 1976-06-10 | 1978-01-06 | Berema Sa | PREPARATION FOR TREATING FAT OVERLOAD AND CELLULITIC INFILTRATES |
FR2357246A1 (en) * | 1976-07-09 | 1978-02-03 | Martinez Gerard | Antiinflammatory and analgesic medicaments - contg. hydrolase, thyroxine and adrenalin and applied topically |
RO76691A2 (en) * | 1979-04-02 | 1981-08-30 | Intreprinderea De Produse Cosmetice "Farmec",Ro | NUTRITIVE CREAM AGAINST WRINKLES |
CH642851A5 (en) * | 1980-02-13 | 1984-05-15 | Berema Sa | Medicinal compositions for the treatment of cellulite |
EP0060776A1 (en) * | 1981-03-11 | 1982-09-22 | Somachim S.A. | Medicaments for the treatment of obesity and hyperlipoidemia |
Non-Patent Citations (7)
Title |
---|
DATABASE EMBASE 1 January 1900 (1900-01-01), AGOSTINI F, CALIFANO L: "PRELIMINARY EVALUATION OF A TOPICAL FORMULATION OF LEVOTHYROXINE PLUS ESCIN IN TREATMENT OF ATROPHIC STRIAE", XP002020417, Database accession no. EMB-1981038096 * |
DATABASE EMBASE 1 January 1900 (1900-01-01), AYRES S, BUCKLEY R H: "ATOPIC DERMATITIS - A NEW THERAPEUTIC REGIMEN", XP002020415, Database accession no. EMB-1984027313 * |
DATABASE EMBASE 1 January 1900 (1900-01-01), BARUFFALDI M, TURCHI G: "TREATMENT OF HYPERTROPHIC AND KELOID SCARS WITH A TOPICAL ASSOCIATION OF 1-THOYROXINE AND ESCIN", XP002020416, Database accession no. EMB-1982189935 * |
DATABASE EMBASE 1 January 1900 (1900-01-01), LISI P: "CLINICAL RESULTS WITH A CREAM CONTAINING LEVOTHYROXINE AND ESCIN", XP002020418, Database accession no. EMB-1974156248 * |
DATABASE WPI Week 8205, Derwent World Patents Index; AN 82-004847, XP002020419 * |
DE RYCKER ET AL.: "Effects of 3,5,3'-triiodothyronine on collagen synthesis by cultured human skin fibroblasts", FEBS LETTERS, vol. 174, no. 1, August 1984 (1984-08-01), ELSEVIER SCIENCE PUBLISHERS, pages 34 - 37, XP002041073 * |
STN, File Supplier, Karlsruhe, DE, File * |
Also Published As
Publication number | Publication date |
---|---|
EP0831769B1 (en) | 2003-10-15 |
PT831769E (en) | 2004-02-27 |
DK0831769T3 (en) | 2004-02-23 |
ES2208753T3 (en) | 2004-06-16 |
DE69630380T8 (en) | 2009-08-06 |
EP1398024A2 (en) | 2004-03-17 |
DE69630380T2 (en) | 2004-08-12 |
CA2223720C (en) | 2008-12-30 |
WO1996040048A2 (en) | 1996-12-19 |
AU6476996A (en) | 1996-12-30 |
ATE251887T1 (en) | 2003-11-15 |
CA2223720A1 (en) | 1996-12-19 |
DE69630380D1 (en) | 2003-11-20 |
EP1398024A3 (en) | 2004-12-15 |
JPH11508241A (en) | 1999-07-21 |
DE69630380T3 (en) | 2009-04-30 |
EP0831769A2 (en) | 1998-04-01 |
ES2208753T5 (en) | 2009-02-01 |
EP0831769B2 (en) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996040048A3 (en) | Novel uses for thyroid hormones or thyroid hormone-like compounds | |
UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
WO1994012880A3 (en) | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression | |
ES8608535A1 (en) | Pharmaceutical composition. | |
NO20003552D0 (en) | Progesterone agonist compounds, pharmaceutical compositions containing them and the use of the compound, as well as a method for determining the presence of steroid receptors, ligand-steroid receptor complexes and a method | |
CA2290622A1 (en) | Selective thyroid hormone analogs | |
AU4699589A (en) | Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5 alpha-reductase | |
UA49799C2 (en) | Cyclo-peptides, method of its producing, pharmaceutical composition containing it, method of producing thereof, method of illness curing, method of immobilized ligands producing | |
AU3504393A (en) | N-sulphonyl-2-oxoindole derivatives having affinity for vasopressin and/or ocytocin receptors | |
CA2196197A1 (en) | Retinoic acid x-receptor ligands | |
NZ331941A (en) | Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis | |
NZ266314A (en) | Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions | |
PL336382A1 (en) | Method of obtaining tricaronylmetal compounds of fac structure and their application in labelling biologically active substrates | |
AU3635089A (en) | Perfume composition, with a continuous aqueous phase, having a high concentration of perfume | |
AU688216B2 (en) | Use of ligands which are specific for RXR receptors | |
Dockray et al. | Biological activity of iodinated gastrins | |
AU7215796A (en) | Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation | |
WO1993003382A3 (en) | Characterization of specific drug receptors with fluorescent ligands | |
KR960702476A (en) | LHRH ANTAGONISTS | |
AU4625496A (en) | Intermetallic ruthenium-tin catalyst for use in aldehyde synthesis | |
WO2000009537A3 (en) | Compounds having growth hormone releasing activity | |
PL309772A1 (en) | Novel compositions based on synegically acting mixture consisting of at least one ligand specific in respect to rxr and at least one ligand specific in respect to rar-a and their application | |
AU3170997A (en) | Complex preparations characterised by a betain content | |
AU7675896A (en) | Sulfur containing di-tert-butylphenol compounds useful as anti-inflammatory agents | |
AU9621598A (en) | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1-35,DESCRIPTION,REPLACED BY NEW PAGES 1-32;PAGES 36-47,CLAIMS,REPLACED BY NEW P$AGES 33-45;PAGES 1/12-12/12,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 33-36,DESCRIPTION,ADDED;PAGES 33-45,CLAIMS,RENUMBERED AS PAGES 37-49 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2223720 Country of ref document: CA Ref country code: CA Ref document number: 2223720 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 502122 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996924268 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08973627 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996924268 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996924268 Country of ref document: EP |